533 related articles for article (PubMed ID: 30472020)
21. Novel KDM5B splice variants identified in patients with developmental disorders: Functional consequences.
Lebrun N; Mehler-Jacob C; Poirier K; Zordan C; Lacombe D; Carion N; Billuart P; Bienvenu T
Gene; 2018 Dec; 679():305-313. PubMed ID: 30217758
[TBL] [Abstract][Full Text] [Related]
22. Histone demethylase KDM5B is a key regulator of genome stability.
Li X; Liu L; Yang S; Song N; Zhou X; Gao J; Yu N; Shan L; Wang Q; Liang J; Xuan C; Wang Y; Shang Y; Shi L
Proc Natl Acad Sci U S A; 2014 May; 111(19):7096-101. PubMed ID: 24778210
[TBL] [Abstract][Full Text] [Related]
23. KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance.
Xu W; Zhou B; Zhao X; Zhu L; Xu J; Jiang Z; Chen D; Wei Q; Han M; Feng L; Wang S; Wang X; Zhou J; Jin H
Int J Biol Sci; 2018; 14(9):1122-1132. PubMed ID: 29989047
[TBL] [Abstract][Full Text] [Related]
24. JARID1B expression and its function in DNA damage repair are tightly regulated by miRNAs in breast cancer.
Mocavini I; Pippa S; Licursi V; Paci P; Trisciuoglio D; Mannironi C; Presutti C; Negri R
Cancer Sci; 2019 Apr; 110(4):1232-1243. PubMed ID: 30588710
[TBL] [Abstract][Full Text] [Related]
25. Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A).
Wong PP; Miranda F; Chan KV; Berlato C; Hurst HC; Scibetta AG
Mol Cell Biol; 2012 May; 32(9):1633-44. PubMed ID: 22371483
[TBL] [Abstract][Full Text] [Related]
26. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
27. JARID1B is a luminal lineage-driving oncogene in breast cancer.
Yamamoto S; Wu Z; Russnes HG; Takagi S; Peluffo G; Vaske C; Zhao X; Moen Vollan HK; Maruyama R; Ekram MB; Sun H; Kim JH; Carver K; Zucca M; Feng J; Almendro V; Bessarabova M; Rueda OM; Nikolsky Y; Caldas C; Liu XS; Polyak K
Cancer Cell; 2014 Jun; 25(6):762-77. PubMed ID: 24937458
[TBL] [Abstract][Full Text] [Related]
28. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.
Chan CM; Martin LA; Johnston SR; Ali S; Dowsett M
J Steroid Biochem Mol Biol; 2002 Aug; 81(4-5):333-41. PubMed ID: 12361723
[TBL] [Abstract][Full Text] [Related]
29. Histone lysine demethylases in breast cancer.
Paolicchi E; Crea F; Farrar WL; Green JE; Danesi R
Crit Rev Oncol Hematol; 2013 May; 86(2):97-103. PubMed ID: 23266085
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway.
Hayami S; Yoshimatsu M; Veerakumarasivam A; Unoki M; Iwai Y; Tsunoda T; Field HI; Kelly JD; Neal DE; Yamaue H; Ponder BA; Nakamura Y; Hamamoto R
Mol Cancer; 2010 Mar; 9():59. PubMed ID: 20226085
[TBL] [Abstract][Full Text] [Related]
31. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
Kristensen LH; Nielsen AL; Helgstrand C; Lees M; Cloos P; Kastrup JS; Helin K; Olsen L; Gajhede M
FEBS J; 2012 Jun; 279(11):1905-14. PubMed ID: 22420752
[TBL] [Abstract][Full Text] [Related]
32. SUMOylation negatively modulates target gene occupancy of the KDM5B, a histone lysine demethylase.
Bueno MT; Richard S
Epigenetics; 2013 Nov; 8(11):1162-75. PubMed ID: 23970103
[TBL] [Abstract][Full Text] [Related]
33. Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer.
Yeh IJ; Esakov E; Lathia JD; Miyagi M; Reizes O; Montano MM
Sci Rep; 2019 Nov; 9(1):17663. PubMed ID: 31776402
[TBL] [Abstract][Full Text] [Related]
34. KDM6B Counteracts EZH2-Mediated Suppression of
Wang W; Lim KG; Feng M; Bao Y; Lee PL; Cai Y; Chen Y; Zhang H; Marzese D; Hoon DSB; Yu Q
Mol Cancer Ther; 2018 Sep; 17(9):1973-1983. PubMed ID: 29925528
[TBL] [Abstract][Full Text] [Related]
35. KDM5 family of demethylases promotes CD44-mediated chemoresistance in pancreatic adenocarcinomas.
Wang D; Zhang Y; Liao Z; Ge H; Güngör C; Li Y
Sci Rep; 2023 Oct; 13(1):18250. PubMed ID: 37880235
[TBL] [Abstract][Full Text] [Related]
36. Structural analysis of human KDM5B guides histone demethylase inhibitor development.
Johansson C; Velupillai S; Tumber A; Szykowska A; Hookway ES; Nowak RP; Strain-Damerell C; Gileadi C; Philpott M; Burgess-Brown N; Wu N; Kopec J; Nuzzi A; Steuber H; Egner U; Badock V; Munro S; LaThangue NB; Westaway S; Brown J; Athanasou N; Prinjha R; Brennan PE; Oppermann U
Nat Chem Biol; 2016 Jul; 12(7):539-45. PubMed ID: 27214403
[TBL] [Abstract][Full Text] [Related]
37. Histone demethylase lysine demethylase 5B in development and cancer.
Han M; Xu W; Cheng P; Jin H; Wang X
Oncotarget; 2017 Jan; 8(5):8980-8991. PubMed ID: 27974677
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells.
Montano MM; Yeh IJ; Chen Y; Hernandez C; Kiselar JG; de la Fuente M; Lawes AM; Nieman MT; Kiser PD; Jacobberger J; Exner AA; Lawes MC
Breast Cancer Res; 2019 Dec; 21(1):138. PubMed ID: 31805991
[TBL] [Abstract][Full Text] [Related]
39. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
Yang F; Xie HY; Yang LF; Zhang L; Zhang FL; Liu HY; Li DQ; Shao ZM
Autophagy; 2020 Jun; 16(6):1061-1076. PubMed ID: 32401166
[TBL] [Abstract][Full Text] [Related]
40. PLU-1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells.
Catchpole S; Spencer-Dene B; Hall D; Santangelo S; Rosewell I; Guenatri M; Beatson R; Scibetta AG; Burchell JM; Taylor-Papadimitriou J
Int J Oncol; 2011 May; 38(5):1267-77. PubMed ID: 21369698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
